晚期前列腺癌的诊疗一体化:当前适应证与未来发展
本综述由核医学医师与泌尿外科医师组成的专家组对晚期前列腺癌诊疗一体化的当前适应证、性能、局限与未来发展进行非系统性回顾。基于前列腺特异性膜抗原(PSMA)的PET显像在晚期前列腺癌中作为诊疗一体化药物备受关注,其影响治疗策略与预后尚不明确;PSMA靶向放射性配体治疗的初步结果似乎在可行性与疗效方面支持其作用,但仍需进一步研究。
要点
- PSMA是晚期前列腺癌显像与治疗的有前景分子。
- PSMA-PET/CT对治疗策略与预后的影响有前景但尚不明确。
- PSMA靶向放射性配体治疗的初步结果似乎支持其可行性与疗效。
核心结论
- PSMA是晚期前列腺癌患者显像与治疗的有前景分子。
- 仍需进一步研究以探讨其作用并确定其副作用影响与整体策略结局。
研究设计与样本
- 由在晚期前列腺癌放射性核素显像与放射性配体治疗领域经验丰富的核医学医师与一名泌尿外科医师组成的专家组进行非系统性综述。
- 综述当前适应证、性能、局限与潜在未来发展。
主要发现
- 在PET放射性示踪剂中,基于PSMA的化合物在晚期前列腺癌中受到持续增长关注,主要因其作为诊疗一体化药物的潜在相关性。
- PSMA-PET/CT显像对治疗策略与预后的影响有前景,但仍不明确。
- 潜在应用可能包括作为PSMA靶向放射性配体治疗的把关者以及监测全身性疾病播散。
- 目前初步结果似乎证实PSMA靶向放射性配体治疗在可行性与疗效方面的作用。
局限性
- 原文为非系统性综述。
- PSMA-PET/CT对治疗策略与预后的影响仍有前景但尚不明确。
- 仍需进一步研究以探讨PSMA的作用并确定其副作用影响与整体策略结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Advanced prostate cancer (PCa) is a prominent cause of cancer death in men; positron emission tomography (PET) imaging may play a relevant role in detecting metastases and thus allowing a more tailored therapy in these patients. Radioligand therapy (RLT) may also gain relevance as a treatment strategy in advanced disease. OBJECTIVE: The aim of this review is to highlight how the recently developed theranostic processes may become a part of both the available diagnostic and the therapy arsenal in advanced PCa patients. EVIDENCE ACQUISITION: An expert panel of nuclear medicine physicians and a urologist, highly experienced in the fields of radionuclide imaging and RLT in advanced PCa, performed a nonsystematic review of the current indications, performance, limitations, and potential future developments of the currently available options in PCa theranostics. EVIDENCE SYNTHESIS: Among PET radiotracers, prostate-specific membrane antigen (PSMA)-based compounds in advanced PCa are the focus of a continuously growing interest, mostly due to their potential relevance as theranostic agents. The impact of PSMA-based PET/computed tomography imaging on treatment strategies and prognosis is promising, but still not unquestionably clear. Potential applications may include a role as a gatekeeper to PSMA-directed RLT, as well as monitoring the spread of systemic disease. Currently, initial results seem to substantiate the role of PSMA-directed RLT in terms of feasibility and efficacy. CONCLUSIONS: PSMA is a promising molecule for both imaging and therapy in advanced PCa patients; nevertheless, further studies are needed to investigate its role and to determine the impact of its side effects and its overall strategy outcome. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA), a protein, is highly expressed on prostate cancer cells. The possibility to perform diagnostic imaging and subsequently administer therapies by the means of the same molecule is called "theranostics". In patients with advanced prostate cancer, PSMA might have a role in detecting disease spread through both positron emission tomography and single-photon emission computed tomography imaging, while treating prostate cancer systemic localizations with radioligand therapy. Further studies are needed to better determine patients' risks and benefits of these therapeutic approaches.
引用
- Farolfi A, Fendler W, Iravani A, et al. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. Eur Urol Oncol. 2019. PMID: 31017091. doi:10.1016/j.euo.2019.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。